R-(-)-β-O-methylsynephrine, a natural product, inhibits VEGF-induced angiogenesis in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 399, Issue 1, 2010, Pages 20-23

  Kim, Nam Hee ^a   Pham, Ngoc Bich ^b   Quinn, Ronald J ^b   Kwon, Ho Jeong ^a  

^a Yonsei University   (South Korea)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Angiogenesis; Natural compound; R ( ) O methylsynephrine; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA O METHYLSYNEPHRINE; FIBROBLAST GROWTH FACTOR; NATURAL PRODUCT; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIS; DRUG ISOLATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RUTACEAE; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL PRODUCTS; CELL LINE, TUMOR; CELLS, CULTURED; CHICK EMBRYO; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SYNEPHRINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RUTACEAE;

EID: 77955569446     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.025     Document Type: Article

References (14)

1. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
2. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235:442-447.
3. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
4. Kiselyov A., Balakin K.V., Tkachenko S.E. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs 2007, 16:83-107.
5. De Falco S., Gigante B., Persico M.G. Structure and function of placental growth factor. Trends Cardiovasc. Med. 2002, 12:241-246.
6. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat. Rev. Cancer 2008, 8:579-591.
7. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70:461-477.
8. Altmann K.H., Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat. Prod. Rep. 2007, 24:327-357.
9. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 2001, 46:3-26.
10. Bergstrom C.A., Strafford M., Lazorova L., Avdeef A., Luthman K., Artursson P. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 2003, 46:558-570.
11. Quinn R.J., Carroll A.R., Pham N.B., Baron P., Palframan M.E., Suraweera L., Pierens G.K., Muresan S. Developing a drug-like natural product library. J. Nat. Prod. 2008, 71:464-468.
12. Hornemann K.M., Neal J.M., McLaughlin J.L. Cactus alkaloids XII: Beta-Phenethylamine alkaloids of the genus Coryphantha. J. Pharm. Sci. 1972, 61:41-45.
13. Shim J.S., Kim J.H., Cho H.Y., Yum Y.N., Kim S.H., Park H.J., Shim B.S., Choi S.H., Kwon H.J. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem. Biol. 2003, 10:695-704.
14. Kim N.H., Jung H.J., Shibasaki F., Kwon H.J. NBBA, a synthetic small molecule, inhibits TNF-alpha-induced angiogenesis by suppressing the NF-kappaB signaling pathway. Biochem. Biophys. Res. Commun. 2010, 391:1500-1505.